ZA948024B - Methods for the treatment of peri-menopausal syndrome - Google Patents

Methods for the treatment of peri-menopausal syndrome

Info

Publication number
ZA948024B
ZA948024B ZA948024A ZA948024A ZA948024B ZA 948024 B ZA948024 B ZA 948024B ZA 948024 A ZA948024 A ZA 948024A ZA 948024 A ZA948024 A ZA 948024A ZA 948024 B ZA948024 B ZA 948024B
Authority
ZA
South Africa
Prior art keywords
peri
treatment
methods
menopausal syndrome
substd
Prior art date
Application number
ZA948024A
Other languages
English (en)
Inventor
George Joseph Cullinan
John David Termine
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA948024B publication Critical patent/ZA948024B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA948024A 1993-10-15 1994-10-13 Methods for the treatment of peri-menopausal syndrome ZA948024B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/138,287 US5391557A (en) 1993-10-15 1993-10-15 Methods for the treatment of peri-menopausal syndrome

Publications (1)

Publication Number Publication Date
ZA948024B true ZA948024B (en) 1996-04-15

Family

ID=22481346

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA948024A ZA948024B (en) 1993-10-15 1994-10-13 Methods for the treatment of peri-menopausal syndrome

Country Status (20)

Country Link
US (1) US5391557A (de)
EP (1) EP0652001B1 (de)
JP (1) JPH07196499A (de)
KR (1) KR950010890A (de)
CN (1) CN1107157A (de)
AT (1) ATE153240T1 (de)
AU (1) AU670394B2 (de)
CA (1) CA2118093A1 (de)
CZ (1) CZ253394A3 (de)
DE (1) DE69403305T2 (de)
DK (1) DK0652001T3 (de)
ES (1) ES2104285T3 (de)
GR (1) GR3023603T3 (de)
HU (1) HUT71229A (de)
IL (1) IL111290A (de)
NO (1) NO943876L (de)
NZ (1) NZ264673A (de)
PH (1) PH31262A (de)
RU (1) RU94036758A (de)
ZA (1) ZA948024B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5534526A (en) * 1993-12-21 1996-07-09 Eli Lilly And Company Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5514704A (en) * 1995-03-13 1996-05-07 Eli Lilly And Company Benzothiophenes to inhibit leukotrienes
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
CA2215902A1 (en) * 1995-04-21 1996-10-24 Charles David Jones Benzothiophenes with novel basic side chains
JPH11510479A (ja) * 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
DK0842169T3 (da) * 1995-06-26 2001-01-29 Lilly Co Eli Benzothiophenforbindelser
NZ331085A (en) * 1996-01-29 2000-06-23 Lilly Co Eli use of 2-phenyl-3-benzoyl-benzo[b]thiophene derivatives for increasing sphincter competence
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
WO1999008526A1 (en) * 1997-08-21 1999-02-25 Eli Lilly And Company Methods for inhibiting temporomandibular disorders
US6103740A (en) * 1997-08-21 2000-08-15 Eli Lilly And Company Methods for lowering platelet counts
AU9105598A (en) * 1997-08-21 1999-03-08 Eli Lilly And Company Methods for inhibiting fibrous inflammatory disease and riedel's thyroiditis
US6096781A (en) 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
FR2777784B1 (fr) * 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6258826B1 (en) 1998-10-13 2001-07-10 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
UA75339C2 (en) 1999-08-31 2006-04-17 Schering Ag Use of mesoprogestins (progesterone receptor modulators) as pharmaceutical components for manufacture of medicament for hormone replacement therapy (hrt)
EP1216037A2 (de) 1999-09-21 2002-06-26 Emory University Verfahren und zusammensetzungen zur behandlung von bluttplätchen-zusammenhängenden krankheiten, mit mpl hemmenden agenten
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
ES2233570T3 (es) * 2000-11-30 2005-06-16 Pfizer Products Inc. Composicion que contiene agonistas/antagosnistas de estrogenos y testosterona para tratar un descenso en el nivel de la hormona testosterona.
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
DE4122484A1 (de) * 1991-07-06 1993-01-07 Teves Gmbh Alfred Schaltungsanordnung zur erkennung von radsensordefekten
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
AU670394B2 (en) 1996-07-11
RU94036758A (ru) 1996-08-27
ES2104285T3 (es) 1997-10-01
PH31262A (en) 1998-06-18
NO943876D0 (no) 1994-10-13
DE69403305D1 (de) 1997-06-26
NZ264673A (en) 1999-08-30
IL111290A0 (en) 1994-12-29
US5391557A (en) 1995-02-21
GR3023603T3 (en) 1997-08-29
CA2118093A1 (en) 1995-04-16
NO943876L (no) 1995-04-18
KR950010890A (ko) 1995-05-15
CN1107157A (zh) 1995-08-23
DK0652001T3 (da) 1997-09-15
AU7579094A (en) 1995-05-04
EP0652001B1 (de) 1997-05-21
HU9402956D0 (en) 1995-02-28
EP0652001A1 (de) 1995-05-10
HUT71229A (en) 1995-11-28
CZ253394A3 (en) 1995-05-17
ATE153240T1 (de) 1997-06-15
JPH07196499A (ja) 1995-08-01
DE69403305T2 (de) 1997-09-25
IL111290A (en) 1999-04-11

Similar Documents

Publication Publication Date Title
IL111290A0 (en) Methods for the treatment of peri-menopausal syndrome
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
HU9403675D0 (en) Methods of inhibiting thrombin
UA26930C2 (uk) Засіб для іhгібуваhhя еhдометріозу
DK0663916T3 (da) O-alkyleret rapamycinderivat og dets anvendelse, især som immunosuppressivt middel
ES538418A0 (es) Un derivado de indol-3-carboxamida
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
DK0652002T3 (da) Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning
NO944915D0 (no) Öking av trambomodulinekspresjon
AU7578694A (en) Methods for treating resistant neoplasms
AU538882B2 (en) 2,3-dihydro-imidazo(1,2-g)pyridazine derivatives
ATE146964T1 (de) Behandlung von katarakt mit prostacyclinverbindungen
ES508415A0 (es) Un procedimiento para preparar nuevos derivados de 1,4-benzotiazina.
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
PH25187A (en) 3,4-dihydro-2-alkyl-3-oxo-n-aryl-2h-(1)benzothieno (3,2-e)-1,2-thiazine-4-carboxamide-1,1-dioxides, pharmaceutical compositions containing the same and method of use thereof
MX9702861A (es) Metodo para inhibir las condiciones asociadas con la bradicinina.